Dyslipidaemia is likely to play a leading role in the cardiovascular risk associated with diabetes. Diabetic dyslipidaemia is characterised by hypertriglyceridaemia, a shift from large low-density lipoprotein (LDL) to smaller denser particles, and reduced high-density lipoprotein (HDL) cholesterol. Dyslipidaemia is closely associated with insulin resistance.
Patients with diabetic dyslipidaemia should receive lipid lowering therapy with statins or fibrates, as appropriate.
Due to the relationship between dyslipidaemia and insulin resistance, treatment of insulin resistance should be included in multifactorial risk factor modification. Thiazolidinediones such as pioglitazone may provide a useful treatment approach.
Taskinen MRStrategies for the management of diabetic dyslipidaemia. Drugs1999;58(suppl 1):47-51.
2.
The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med1998;339:1349-57.
3.
Sacks FM, Pfeffer MA, Moyé LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol And Recurrent Events Trial Investigators. N Engl J Med1996 ;335:1001-9.
4.
The Scandinavian Simvastatin Survival Study Group.Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet1994;344:1383-9.
5.
Shepherd J., Cobbe SM, Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med1995;333:1301-7.
6.
Elkeles RS, Diamond JR, Poulter C. et al. Cardiovascular outcomes in Type
7.
diabetes. A double-blind placebo-controlled study of bezafibrate: the St Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care1998;21:641-8.
Pyörälä K., Pedersen TR, Kjekshus J., Faergeman O., Olsson AG, Thorgeirsson G.Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care1997;20:614-20.
10.
Goldberg RB, Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. Circulation1998;98:2513-9.
11.
Turner RC, Millns H., Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RRRisk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ1998;316:823-8.
12.
Hanefeld M. , Fischer S., Julius U. et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia1996;39:1577-83.
13.
Fontbonne A. , Eschwege E., Cambien F. et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study . Diabetologia1989;32:300-4.
14.
Sowers JR, Lester MADiabetes and cardiovascular disease. Diabetes Care1999;22(suppl 3):C14-C20.
15.
Elchebly M. , Porokhov B., Pulcini T., Berthezène F., Ponsin G.Alterations in composition and concentration of lipoproteins and elevated cholesteryl ester transfer in non-insulin-dependent diabetes mellitus (NIDDM). Atherosclerosis1996;123:93-101.
16.
Calvo C., Talussot C., Ponsin G., Berthezène F.Non-enzymatic glycation of apolipoprotein A-1. Effects on its self-association and lipid binding properties. Biochem Biophys Res Comm1988;153:1060-7.
17.
Hedrick CC, Thorpe SR, FU M-X et al. Glycation impairs high-density lipoprotein function. Diabetologia2000;43:312-20.
18.
Tilly-Kiesi M., Syvanne M., Kuusi T., Lahdenpera S., Taskinen MRAbnormalities of low density lipoproteins in normolipidaemic Type II diabetic and nondiabetic patients with coronary artery disease. J Lipid Res1992;33:333-42.
19.
Calvo C., Luo B.-Y, Puygranier F., Ponsin G., Berthezène F.Characterization and metabolism of glycated high density lipoproteins in diabetic patients. Adv Exp Med Biol1988 ;243:165-72.
20.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet1998;352:837-53.
21.
Gaudet D., Vohl MC, Perron P. et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation1998;97:871-7.
22.
Garg A., Bonanome A., Grundy SM, Zhang ZJ, Unger RHComparison of a high-carbohydrate diet with a high-monounsaturated-fat diet in patients with non-insulin-dependent diabetes mellitus. N Engl J Med1988;319:829-34.
23.
Tikkanen MJ , Laakso M., Ilmonen M. et al. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. Diabetes Care1998;21:477-1.
24.
Charatan F.Bayer decides to withdraw cholesterol lowering drug. BMJ2001;323:359.
25.
Sacks FM, Tonkin AM, Shepherd J. et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project . Circulation2000;102:1893-900.
26.
The BIP Study Group.Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation2000;102:21-7.
27.
Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low- levels of high-density lipoprotein cholesterol. N Engl J Med1999;341:410-8.
28.
Després J-P. , Lamarche B., Mauriège P., Cantin B., Dagenais GR, Moorjani S., Lupien P.-J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med1996;334:952-7.
